IL33 and neoplasm: In the case of gastric cancer, Zhou Q. et al. (2020) highlighted the fact that among tumor-stroma interactions, the upregulation of interleukin 33 (IL-33) and its receptor suppressor of tumorigenicity 2 (ST2L) led to the production of Il-33 derived CAFS, which enhanced the migration and invasion of cancer cells by inducing EMT through activation of the ERK1/2-specific protein 1 (SP1)-zinc finger E-box binding homeobox 2 (ZEB2) pathway in a ST2L-dependent manner.